MX382757B - Inhibidor del sistema complemento de ornithodoros moubata para utilizarse en el tratamiento de enfermedades mediadas por el sistema complemento en pacientes con polimorfismo de c5. - Google Patents
Inhibidor del sistema complemento de ornithodoros moubata para utilizarse en el tratamiento de enfermedades mediadas por el sistema complemento en pacientes con polimorfismo de c5.Info
- Publication number
- MX382757B MX382757B MX2016016139A MX2016016139A MX382757B MX 382757 B MX382757 B MX 382757B MX 2016016139 A MX2016016139 A MX 2016016139A MX 2016016139 A MX2016016139 A MX 2016016139A MX 382757 B MX382757 B MX 382757B
- Authority
- MX
- Mexico
- Prior art keywords
- complement system
- complement pathway
- polymorphism
- complement
- patients
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 230000000295 complement effect Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 241000238890 Ornithodoros moubata Species 0.000 title 1
- 230000004154 complement system Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000024203 complement activation Effects 0.000 abstract 6
- 102000004856 Lectins Human genes 0.000 abstract 2
- 108090001090 Lectins Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 150000002066 eicosanoids Chemical class 0.000 abstract 2
- 239000002523 lectin Substances 0.000 abstract 2
- 102100031506 Complement C5 Human genes 0.000 abstract 1
- 108010028773 Complement C5 Proteins 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 102000054765 polymorphisms of proteins Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1410116.6A GB201410116D0 (en) | 2014-06-06 | 2014-06-06 | Method of treatment |
| PCT/EP2015/062742 WO2015185760A1 (en) | 2014-06-06 | 2015-06-08 | Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with c5 polymorphism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016016139A MX2016016139A (es) | 2017-07-28 |
| MX382757B true MX382757B (es) | 2025-03-13 |
Family
ID=51266841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016016139A MX382757B (es) | 2014-06-06 | 2015-06-08 | Inhibidor del sistema complemento de ornithodoros moubata para utilizarse en el tratamiento de enfermedades mediadas por el sistema complemento en pacientes con polimorfismo de c5. |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11052129B2 (enExample) |
| EP (1) | EP3151851B1 (enExample) |
| JP (2) | JP7045133B2 (enExample) |
| KR (1) | KR102439717B1 (enExample) |
| CN (1) | CN106659767B (enExample) |
| AU (1) | AU2015270396B2 (enExample) |
| BR (1) | BR112016028446A2 (enExample) |
| CA (1) | CA2951175A1 (enExample) |
| DK (2) | DK3151851T3 (enExample) |
| ES (2) | ES2906630T3 (enExample) |
| GB (1) | GB201410116D0 (enExample) |
| IL (1) | IL249237B (enExample) |
| MX (1) | MX382757B (enExample) |
| PL (2) | PL3151851T3 (enExample) |
| RU (1) | RU2700932C2 (enExample) |
| WO (1) | WO2015185760A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201410116D0 (en) | 2014-06-06 | 2014-07-23 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| CA2988313A1 (en) * | 2015-06-08 | 2016-12-15 | Volution Immuno Pharmaceuticals Sa | Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease |
| GB201602802D0 (en) * | 2016-02-17 | 2016-03-30 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| JP2019521105A (ja) * | 2016-06-07 | 2019-07-25 | ノバルティス アーゲー | 補体ｃ５多型を有する患者を治療するための抗ｃ５抗体 |
| SE540754C2 (en) * | 2016-11-30 | 2018-10-30 | Ikea Supply Ag | Molding of fiber blanks into three-dimensional fiber block |
| ES2945433T3 (es) * | 2017-04-21 | 2023-07-03 | Volution Immuno Pharmaceuticals Sa | Coversina para el tratamiento de enfermedades ampollares autoinmunes |
| JP7153669B2 (ja) * | 2017-04-21 | 2022-10-14 | ヴォリューション イミュノ ファーマシューティカルズ エスエイ | 瘢痕性眼炎症障害の治療のためのコバーシン |
| WO2019186084A1 (en) * | 2018-03-26 | 2019-10-03 | The University Of Liverpool | Anti-complement histones |
| EP3849588A1 (en) * | 2018-09-10 | 2021-07-21 | Volution Immuno Pharmaceuticals SA | Coversin for use in the treatment of rheumatic diseases |
| GB201905810D0 (en) * | 2019-04-25 | 2019-06-05 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| GB202218084D0 (en) | 2022-12-01 | 2023-01-18 | Volution Immuno Pharmaceuticals Sa | Fusion proteins |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050054033A9 (en) | 1995-08-30 | 2005-03-10 | Human Genome Sciences, Inc. | Methods and compositions for treating and preventing infection using human interferon regulatory factor 3 |
| DE602004020334D1 (de) | 2003-06-02 | 2009-05-14 | Varleigh Ltd | Komplementinhibitoren aus zecken |
| GB0312619D0 (en) * | 2003-06-02 | 2003-07-09 | Evolutec Ltd | Complement inhibitors |
| GB0518443D0 (en) | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
| GB0617734D0 (en) * | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
| WO2008029169A2 (en) | 2006-09-08 | 2008-03-13 | Varleigh Limited | Method of treating respiratory disorders |
| GB0802116D0 (en) | 2008-02-05 | 2008-03-12 | Natural Enviromental Res Counc | Treatment |
| GB0906779D0 (en) | 2009-04-20 | 2009-06-03 | Natural Environment Res Council | Composition |
| NZ601018A (en) * | 2010-01-08 | 2013-09-27 | Varleigh Immuno Pharmaceuticals Ltd | Ev576 for use in the treatment of viral infections of the respiratory tract |
| TW201418707A (zh) * | 2012-09-21 | 2014-05-16 | Alexion Pharma Inc | 補體組分ｃ５拮抗劑之篩選分析 |
| GB201410116D0 (en) | 2014-06-06 | 2014-07-23 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| ES2945433T3 (es) | 2017-04-21 | 2023-07-03 | Volution Immuno Pharmaceuticals Sa | Coversina para el tratamiento de enfermedades ampollares autoinmunes |
-
2014
- 2014-06-06 GB GBGB1410116.6A patent/GB201410116D0/en not_active Ceased
-
2015
- 2015-06-08 JP JP2016571246A patent/JP7045133B2/ja active Active
- 2015-06-08 CA CA2951175A patent/CA2951175A1/en active Pending
- 2015-06-08 KR KR1020167036998A patent/KR102439717B1/ko active Active
- 2015-06-08 AU AU2015270396A patent/AU2015270396B2/en active Active
- 2015-06-08 PL PL15728491T patent/PL3151851T3/pl unknown
- 2015-06-08 MX MX2016016139A patent/MX382757B/es unknown
- 2015-06-08 US US15/315,136 patent/US11052129B2/en active Active
- 2015-06-08 RU RU2016151179A patent/RU2700932C2/ru active
- 2015-06-08 ES ES15728491T patent/ES2906630T3/es active Active
- 2015-06-08 CN CN201580040646.5A patent/CN106659767B/zh active Active
- 2015-06-08 EP EP15728491.0A patent/EP3151851B1/en active Active
- 2015-06-08 DK DK15728491.0T patent/DK3151851T3/da active
- 2015-06-08 BR BR112016028446A patent/BR112016028446A2/pt active Search and Examination
- 2015-06-08 WO PCT/EP2015/062742 patent/WO2015185760A1/en not_active Ceased
- 2015-12-09 ES ES15807907T patent/ES2906632T3/es active Active
- 2015-12-09 JP JP2017563314A patent/JP6767396B2/ja not_active Expired - Fee Related
- 2015-12-09 US US15/577,906 patent/US20180193417A1/en not_active Abandoned
- 2015-12-09 PL PL15807907T patent/PL3302519T3/pl unknown
- 2015-12-09 DK DK15807907.9T patent/DK3302519T3/da active
-
2016
- 2016-11-27 IL IL249237A patent/IL249237B/en active IP Right Grant
-
2021
- 2021-05-28 US US17/333,675 patent/US20210283221A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX382757B (es) | Inhibidor del sistema complemento de ornithodoros moubata para utilizarse en el tratamiento de enfermedades mediadas por el sistema complemento en pacientes con polimorfismo de c5. | |
| MX2016000364A (es) | Metodos para tratar o prevenir afecciones oftalmologicas. | |
| CR20190311A (es) | Composiciones para tratar afecciones inflamatorias | |
| BR112015009948A8 (pt) | Antagonistas de ativina-actrii, usos dos mesmos para tratamento de doenças ósseas e outros distúrbios e método para monitorar a eficácia do tratamento ou prevenção de uma doença óssea e outros distúrbios | |
| BR112017003546A2 (pt) | amidas heterocíclicas como inibidores de rip1 quinase como medicamentos | |
| MX2016010854A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de un antagonista de il-4r. | |
| MX2017010982A (es) | Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer. | |
| MX381283B (es) | Tratamiento de pénfigo. | |
| MX2016016380A (es) | Composicion farmaceutica para usarse en la prevencion y/o tratamiento de enfermedades que se desarrollan o progresan como resultado de una disminucion o perdida de actividad del factor viii de coagulacion sanguinea activado. | |
| MX2022007221A (es) | Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos. | |
| BR112017002637A2 (pt) | métodos para tratar ou prevenir condições oftalmológicas | |
| BR112015020466A2 (pt) | inibidores de cdc7 | |
| MX2017016134A (es) | Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad. | |
| MX2018004170A (es) | Biomarcadores relacionados con enfermedades mediadas por interleucina-33 (il-33) y usos de los mismos. | |
| HN2012000023A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
| PH12016500140A1 (en) | Heterobicycloaryl rorc2 inhibitors and methods of use thereof | |
| BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
| MX354123B (es) | Composición antiséptica oral para tratamiento de mucositis oral. | |
| MX392677B (es) | Composiciones para usarse en el tratamiento de trastornos neurodegenerativos en una población particular de pacientes. | |
| BR112018015367A2 (pt) | carreadores oromucosais de nanofibra para tratamento terapêutico | |
| CL2019000625A1 (es) | Combinación de agonistas de fxr. | |
| MX387839B (es) | Laminina para usarse en el tratamiento de una enfermedad, un trastorno o una afección de un endotelio de córnea. | |
| PH12015502266A1 (en) | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers | |
| MA39447A1 (fr) | (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
| BR112016026470A8 (pt) | composto modulador de hsp70, composição farmacêutica que o compreende e uso do referido composto |